Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International, Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2a Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

X
Trial Profile

International, Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2a Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BP 101 (Primary)
  • Indications Decreased libido; Female sexual dysfunction
  • Focus Therapeutic Use
  • Sponsors Ivix
  • Most Recent Events

    • 05 Jan 2021 According to an Ovoca Bio media release, upon confirming the submission, the Minzdrav will automatically commence a review process, which is expected to be a minimum of nine months duration.
    • 05 Jan 2021 According to an Ovoca Bio media release, based on the two Phase 1 studies, a Phase 2a study and the pivotal Phase 3 study, the company has resubmitted the Marketing Authorisation (MA) to the Russian Ministry of Health (Minzdrav) on 30 Dec 2020. The MA submission was not granted following the identification of issues relating to the chemistry, manufacturing and controls (CMC) and labelling sections of the MA submission dossier.
    • 15 Aug 2017 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top